Latest news and press releases about Actuate Therapeutics Inc (ACTU): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Price
| Price | $1.00 |
| Market Cap | $24M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 27.40 |
| EV / EBITDA | -5.22 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -280.51% |
| Return on Invested Capital | -270.08% |
| Return on Assets | -158.36% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · ELTX · MCRB · MOLN · NKTX · PEPG
Explore sector: Healthcare · Biotechnology
More sections of ACTU: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks